Restless legs syndrome: Difference between revisions
No edit summary |
|||
| Line 37: | Line 37: | ||
==Treatment== | ==Treatment== | ||
[[Restless legs syndrome medical therapy|Medical Therapy]] | [[Restless legs syndrome surgery | Surgery]] | [[Restless legs syndrome primary prevention|Primary Prevention]] | [[Restless legs syndrome secondary prevention|Secondary Prevention]] | [[Restless legs syndrome cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Restless legs syndrome future or investigational therapies|Future or Investigational Therapies]] | [[Restless legs syndrome medical therapy|Medical Therapy]] | [[Restless legs syndrome surgery | Surgery]] | [[Restless legs syndrome primary prevention|Primary Prevention]] | [[Restless legs syndrome secondary prevention|Secondary Prevention]] | [[Restless legs syndrome cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Restless legs syndrome future or investigational therapies|Future or Investigational Therapies]] | ||
==Case Studies== | |||
[[Restless legs syndrome case study one|Case #1]] | |||
==Controversies== | ==Controversies== | ||
Recently, several major pharmaceutical companies are reported to be marketing drugs without an explicit approval for RLS, which are "off-label" applications for drugs approved for other diseases. The Restless Leg Foundation <ref>* [http://www.rls.org/NETCOMMUNITY/Page.aspx?&pid=471&srcid=-2 RLS Foundation]</ref> received 44% of its $1.4 million in funding from these pharmaceutical groups<ref>[http://www.newscientist.com/channel/health/mg19225755.100-patient-groups-special-swallowing-the-best-advice.html Marshall, Jessica, and Peter Aldhous. "Patient Groups Special." New Scientist, 10/26/06]</ref>. This has called into question the neutrality of this group (significant conflict of interest issue) and the course of action which they recommend to RLS patients. | Recently, several major pharmaceutical companies are reported to be marketing drugs without an explicit approval for RLS, which are "off-label" applications for drugs approved for other diseases. The Restless Leg Foundation <ref>* [http://www.rls.org/NETCOMMUNITY/Page.aspx?&pid=471&srcid=-2 RLS Foundation]</ref> received 44% of its $1.4 million in funding from these pharmaceutical groups<ref>[http://www.newscientist.com/channel/health/mg19225755.100-patient-groups-special-swallowing-the-best-advice.html Marshall, Jessica, and Peter Aldhous. "Patient Groups Special." New Scientist, 10/26/06]</ref>. This has called into question the neutrality of this group (significant conflict of interest issue) and the course of action which they recommend to RLS patients. | ||
Revision as of 15:56, 10 June 2013
| Restless legs syndrome | |
 | |
|---|---|
| Sleep pattern of a Restless Legs Syndrome patient (red) vs. a healthy sleep pattern (blue). |
|
Restless legs syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Restless legs syndrome On the Web |
|
American Roentgen Ray Society Images of Restless legs syndrome |
|
Risk calculators and risk factors for Restless legs syndrome |
For patient information click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Synonyms and keywords: Wittmaack-Ekbom's syndrome; RLS
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Restless legs syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria | History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Case Studies
Controversies
Recently, several major pharmaceutical companies are reported to be marketing drugs without an explicit approval for RLS, which are "off-label" applications for drugs approved for other diseases. The Restless Leg Foundation [1] received 44% of its $1.4 million in funding from these pharmaceutical groups[2]. This has called into question the neutrality of this group (significant conflict of interest issue) and the course of action which they recommend to RLS patients.
Related Chapters
References
Template:Diseases of the nervous system
ca:Síndrome de les cames neguitoses de:Restless-Legs-Syndrom ms:Sindrom kaki resah fi:Levottomat jalat sv:Rastlösa ben